June 24th 2025, 5:00pm
Dr. Rita Mukhtar sits down for a conversation with Dr. Joshua Sabari to discuss the potential use of ctDNA to guide breast cancer therapy.
June 23rd 2025, 1:00pm
Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.
June 22nd 2025, 2:00pm
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
June 20th 2025, 4:00pm
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.
June 19th 2025, 7:00pm
Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.
June 19th 2025, 4:00pm
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
June 18th 2025, 4:26pm
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
June 18th 2025, 1:00pm
For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.
June 17th 2025, 1:00pm
Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.
June 16th 2025, 8:00pm
Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.
Dispelling Myths and Raising Awareness of Lung Cancer Risk
Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
Venclexta And Azacitidine Fail to Improve MDS Survival
What Does a Blood Cancer Diagnosis Mean?